Search results
Showing 51 to 100 of 1327 results for nice quality standards or clinical guidelines
How to register as a stakeholder with NICE.
How to register as a stakeholder with NICE.
How we collect and use your personal information, and your rights under data protection legislation.
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual
We have a library of over 200 quality standards and a single menu of indicators, designed to help define and measure quality in health, public health and social care.
Using NICE guidance in social work: scenarios for principal social workers
Home Implementing NICE guidance Social care...
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
This quality standard covers the recognition, diagnosis and early management of suspected sepsis in people over 16 who are not or have not recently been pregnant. It describes high-quality care in priority areas for improvement.
View quality statements for QS213Show all sections
Sections for QS213
- Quality statements
- Quality statement 1: Assessment in acute settings
- Quality statement 2: Assessment outside acute settings
- Quality statement 3: Urgent assessment and antibiotic treatment for people at high risk
- Quality statement 4: Intravenous fluids
- Quality statement 5: Escalation of care
- Quality statement 6: Information for people whose condition is managed outside acute hospital settings
- Update information
This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)
This guideline covers the recognition, diagnosis and early management of suspected sepsis in people aged 16 or over who are not and have not recently been pregnant. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Suspected sepsis in under 16s: recognition, diagnosis and early management (NG254)
This guideline covers the recognition, diagnosis and early management of suspected sepsis in under 16s (not pregnant or recently pregnant). It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
Low-energy contact X-ray brachytherapy for rectal cancer (HTG763)
Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.
This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.
This indicator covers the percentage of diagnoses of sore throat in the preceding 12 months with a recorded FeverPain or Centor score. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.
Cabotegravir for preventing HIV-1 in adults and young people (TA1106)
Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.
Resources, case studies and patient decision aids to show how you can use evidence to improve care and services
Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Processes and methods for NICE-wide guidance surveillance (PMG49)
This guide describes the methods and processes that NICE follows to assess the impact of new evidence, changes to the health and care system, or other new, relevant information that has come to light after NICE guidance has published
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE
Tell us what matters to you, your organisation or your community.
Tell us what matters to you, your organisation or your community.
This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information
This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information
Home Implementing NICE guidance...
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Find out more about NICE technology appraisals advisory committee D members
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Find out more about NICE technology appraisals advisory committee D members
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS74Show all sections
Sections for QS74
- Quality statements
- Quality statement 1: CT head scans
- Quality statement 2: CT head scans for people taking anticoagulants
- Quality statement 3: CT cervical spine scans
- Quality statement 4: Provisional radiology reports
- Quality statement 5: Access to neuroscience units
- Quality statement 6: Inpatient rehabilitation for people with traumatic brain injury
- Quality statement 7: Community rehabilitation services for people with traumatic brain injury
Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)
This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.
Show all sections
Sections for NG252
- Overview
- Designing and commissioning rehabilitation services
- Assessing rehabilitation needs and goal setting
- Rehabilitation planning and delivery
- Information, advice and learning as part of rehabilitation
- Rehabilitation to maintain, improve or support function
- Rehabilitation to support education, work, social and leisure activities, relationships and sex
- Terms used in this guideline
Tackling variation in rehab for people with neurological conditions
NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Biographies and registered interests for members of the Technology Appraisal Committee C
Biographies and registered interests for members of the Technology Appraisal Committee C
Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.
Show all sections
Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery
New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD.
"position":2,"item":{"@id":"/about-us","name":"About us"}}]} Structure of NICE NICE is an organisation made up of people...
Learn from NICE International, part of the UK's National Institute for Health and Care Excellence, about how to improve your nation's health and wellbeing